dc.contributor
Institut Català de la Salut
dc.contributor
[Fernández-Montes A] Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. [Alcaide J] Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. [Alsina M] Medical Oncology Department, Hospital Universitario de Navarra (HUN), Pamplona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Custodio AB] Medical Oncology Department, Hospital Universitario la Paz, CIBERONC Madrid, Spain. [Franco LF] Medical Oncology Department, Hospital Virgen de la Salud, Toledo, Spain. [Gallego Plazas J] Medical Oncology Department, Hospital General Universitario de Elche, Elche, Alicante, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Fernández Montes, Ana
dc.contributor.author
Alcaide, Julia
dc.contributor.author
Alsina Maqueda, Maria
dc.contributor.author
Custodio, Ana
dc.contributor.author
Fernández Franco, Lourdes
dc.contributor.author
Gallego Plazas, Javier
dc.date.accessioned
2025-10-24T09:34:24Z
dc.date.available
2025-10-24T09:34:24Z
dc.date.issued
2022-08-12T06:31:17Z
dc.date.issued
2022-08-12T06:31:17Z
dc.identifier
Fernández-Montes A, Alcaide J, Alsina M, Belén Custodio A, Fernández Franco L, Gallego Plazas J, et al. SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clin Transl Oncol. 2022 Apr;24:658–69.
dc.identifier
https://hdl.handle.net/11351/7993
dc.identifier
10.1007/s12094-022-02801-2
dc.identifier
000773969100002
dc.identifier.uri
https://hdl.handle.net/11351/7993
dc.description.abstract
Diagnosis; Esophageal cancer; Treatment
dc.description.abstract
Diagnóstico; Cáncer de esófago; Tratamiento
dc.description.abstract
Diagnòstic; Càncer d'esòfag; Tractament
dc.description.abstract
Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care.
dc.format
application/pdf
dc.relation
Clinical and Translational Oncology;24
dc.relation
https://doi.org/10.1007/s12094-022-02801-2
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esòfag - Càncer - Tractament
dc.subject
Esòfag - Càncer - Diagnòstic
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Esophageal Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias del esófago
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia
dc.title
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
